Advertisement

Topics

Latest Biotechnology, Pharmaceutical and Healthcare News from Globe Newswire

07:15 EST 19th February 2018 | BioPortfolio

Here are the most relevant search results for "Globe Newswire" found in our extensive news archives from over 250 global news sources.

More Information about Globe Newswire on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Globe Newswire for you to read. Along with our medical data and news we also list Globe Newswire Clinical Trials, which are updated daily. BioPortfolio also has a large database of Globe Newswire Companies for you to search.

Showing News Articles 1–25 of 39,000+ from Globe Newswire

Sunday 18th February 2018

Oasmia Pharmaceutical’s Docecal program achieves significant development milestone

Oasmia Pharmaceutical AB announces that all patients have been treated in the two ongoing studies with Docecal in metastatic breast cancer. Uppsala, Sweden, February 19, 2018 – Oasmia Pharmaceutical AB (NASDAQ: OASM), a developer of a new generation of drugs within human and veterinary oncology, have since 2016 been conducting a, pharmacokinetic cross-over clinical phase I study and a rando...

Saturday 17th February 2018

MediciNova Announces Upcoming Presentation of the SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in Progressive MS at the American Academy of Neurology (AAN) 70th Annual Meeting in Los Angeles, California

LA JOLLA, Calif., Feb. 18, 2018 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that an abstract regarding the completed SPRINT-MS Phase 2b Trial of MN-166 (ibudilast) in progressive multiple sclerosis (progressive MS), which was conducted...

Friday 16th February 2018

New Data in Pediatric Patients with Axillary Hyperhidrosis Presented During Late-Breaking Research Forum at the 76th Annual Meeting of the American Academy of Dermatology

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- Dermira, Inc. (NASDAQ:DERM), a biopharmaceutical company dedicated to bringing biotech ingenuity to medical dermatology by delivering differentiated, new therapies to the millions of patients living with chronic skin conditions, today presented new findings from its glycopyrronium tosylate (formerly DRM04) Phase 3 clinical program. The data showed ...

AnaptysBio Presents Updated Data from ANB020 Phase 2a Atopic Dermatitis Trial at AAD Annual Meeting

SAN DIEGO, Feb. 17, 2018 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq:ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation, today announced that updated data from the company’s Phase 2a trial of ANB020, AnaptysBio’s wholly-owned anti-IL-33 antibody program, in adult patients with moderate-to-seve...

Galapagos and MorphoSys present results from a Phase 1 study with MOR106 in atopic dermatitis as late-breaking abstract at the American Academy of Dermatology (AAD) meeting in San Diego

MOR106 was generally well tolerated in atopic dermatitis (AD) patients 83% of patients (5 out of 6) at the highest dose reached at least 50% improvement per the atopic dermatitis area and severity index (EASI-50) at week 4 Pooled data across dose cohorts showed 72% improvement of AD symptoms at week 12 compared to baseline in patients treated with MOR106 Phase 2 development of MOR106 p...

Thursday 15th February 2018

OncBioMune Provides Update on Market Activity

BATON ROUGE, La., Feb. 16, 2018 (GLOBE NEWSWIRE) -- OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) ("OncBioMune" or the "Company"), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, wishes to make the following statements regarding recent market activity in its common stock traded on the...

Pernix Therapeutics Announces Launch of Authorized Generic Version of Treximet® by Company’s Subsidiary, Macoven Pharmaceuticals

MORRISTOWN, N.J., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, today announced the launch of an authorized generic version of Treximet® (sumatriptan/naproxen sodium) in the U.S. by the Company’s subsidiary, Macoven Pharmaceuticals, LLC.  Treximet is a prescription medicine that contains sumatriptan and naproxen sodi...

HydRx Farms Ltd. (d/b/a Scientus Pharma Inc.) Announces Completion of its $15.8 Million Private Placement Offering of Common Shares

THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Scientus Pharma Inc. (“Scientus” or the “Company”) is pleased to announce that it has completed a private placement offering of common shares of the Company (the “Comm...

AIT Therapeutics Announces $9.82 Million Private Placement

NEW YORK, Feb. 16, 2018 (GLOBE NEWSWIRE) -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, today announced that it has completed a private placement with a select group of investors, which, assuming the exercise of the Tranche A p...

BioStem Technologies Inc. Applies for Uplisting to the OTCQX Market

Pompano Beach, FL, Feb. 16, 2018 (GLOBE NEWSWIRE) -- BioStem Technologies, Inc. (OTC PINK: BSEM) (“BioStem” or the “Company”), a global life sciences corporation, providing innovative technologies with a concentration in Pharmaceuticals and Regenerative Medicine, announced today that it has completed its application to uplist on OTCQX, a higher tier Over The Counter (OTC) market overs...

Editas Medicine Names Jessica Hopfield, Ph.D., to Board of Directors

CAMBRIDGE, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced the appointment of Jessica Hopfield, Ph.D., to its Board of Directors, effective immediately. Dr. Hopfield will also serve on the Audit Committee of the Board. Dr. Hopfield is a scientist and business leader with more than two decades of experience in t...

NewLink Genetics to Host Its Fourth Quarter and Year End 2017 Financial Results Conference Call on March 1, 2018

AMES, Iowa, Feb. 16, 2018 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (NASDAQ:NLNK) today announced that it will release its fourth quarter and year end 2017 financial results on Thursday, March 1, 2018.  The company has scheduled a conference call for 4:30 PM ET the same day to discuss the results and to give an update on clinical and business development activities. NewLink Genetics...

Athenex to Present at 2018 RBC Capital Markets Healthcare Conference

BUFFALO, N.Y., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (Nasdaq:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of cancer and related conditions, today announced Dr. Johnson Lau, Chief Executive Officer, will present at the 2018 RBC Capital Markets Healthcare Conference in New York City on Wedn...

Arcturus Therapeutics Comments on Amended 13D Filing

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ:ARCT), a leading RNA medicines company, today commented on the amended 13D filing by Joseph E. Payne, who was fired from Arcturus as of February 1, 2018, for conduct that its Board of Directors deemed to be contrary to the best interests of the Company and its shareholders. As part of the amended 13D filing,...

Repligen to Report Fourth Quarter and Full Year 2017 Financial Results

WALTHAM, Mass., Feb. 16, 2018 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ:RGEN) today announced that the Company will report fourth quarter and full year 2017 financial results on Thursday, February 22, 2018. The Company will issue a press release before the market opens and will host a conference call at 8:30 a.m. EST to discuss business updates and financial results for the three and t...

Lexicon Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Financial Results Conference Call and Webcast on February 22, 2018

THE WOODLANDS, Texas, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq:LXRX), will release its fourth quarter and full-year 2017 financial results on Thursday, February 22, 2018 before market opens. Management will conduct a conference call and live webcast at 8:00 a.m. EST (7:00 a.m. CST) that day to discuss the financial results and to provide a business update. Dia...

Apricus Biosciences Receives Complete Response Letter from FDA for Vitaros™

SAN DIEGO, Feb. 16, 2018 (GLOBE NEWSWIRE) -- Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the New Drug Application (“NDA”) of Vitaros™ (alprostadil, DDAIP.HCl), a topical cream for...

ALK’s partner, Torii, gains paediatric approval for the house dust mite SLIT-tablet in Japan

  ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) today announced that its partner for Japan, Torii, has gained approval from the Japanese Ministry of Health, Labour and Welfare, to expand the use of ALK’s house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet MITICURE™ to include paediatric allergic rhinitis patients.

ABLYNX ANNOUNCES OPTION EXERCISE BY SANOFI FOR TWO ADDITIONAL MULTI-SPECIFIC NANOBODY PRODUCT CANDIDATES

REGULATED INFORMATION - INSIDE INFORMATION GHENT, Belgium, 16 February 2018 - Ablynx [Euronext Brussels and Nasdaq: ABLX] today announced that Sanofi has exercised its option to license two additional target combinations as part of the research collaboration signed in July 2017, focussed on developing and commercialising Nanobody®-based therapeutics for the treatment of various immune-m...

Amicus Therapeutics Prices Underwritten Offering of Common Stock

CRANBURY, N.J., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the pricing of an underwritten offering of 19,354,839 shares of its common stock at $15.50 per share. The gross proceeds from the offering to Amicus are expected to be $300 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Amicus. In a...

Wednesday 14th February 2018

Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analysis technology for targeting and treating cancer, announced today that Mark R. Baker, Chief Executive Officer, will present at the 2018 RBC Capital Markets Global Healthcare Conference in New York City on Thursday, February 22, 2018 a...

Portola Pharmaceuticals to Announce Fourth Quarter and Full Year 2017 Financial Results and Host Conference Call on Wednesday, February 28, 2018

SOUTH SAN FRANCISCO, Calif., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc.® (NASDAQ:PTLA) today announced that it will host a webcast and conference call to discuss the Company’s financial results for the fourth quarter and full year ended December 31, 2017, and provide a general business overview on Wednesday, February 28, 2018, at 4:30 p.m. ET (1:30 p.m. PT). Conf...

Ovid Therapeutics to Present at the RBC Capital Markets 2018 Global Healthcare Conference

NEW YORK, Feb. 15, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Yaron Werber, MD, chief business and financial officer of Ovid, will present a corporate overview at the RBC Capital Markets 2018 Global Healthcare Conference on Thursday, February 22...

Dova Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Operating and Financial Results

DURHAM, N.C., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ:DOVA), a pharmaceutical company focused on acquiring, developing, and commercializing drug candidates for rare diseases where there is a high unmet need, today reported its operating and financial results for the fourth quarter and full-year ended December 31, 2017. Fourth Quarter and Recent Highlights New D...

Akcea Announces FDA Advisory Committee Meeting to Review Volanesorsen as a Treatment for Familial Chylomicronemia Syndrome

CAMBRIDGE, Mass., Feb. 15, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced that the Division of Metabolism and Endocrinology Products of the U.S. Food and Drug Administration (FDA) will...


Advertisement
Quick Search
Advertisement
Advertisement

 

News Quicklinks